[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"evan-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:evan-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100517225","phase-2-anti-cd38-antibody-treating-evans-syndrome-100517225",false,"NCT06014775","Anti-CD38 Antibody Treating Evans Syndrome","A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Evans Syndrome","2023-D-ES","Inclusion Criteria:\n\n* Male or female aged ≥18 years.\n* Prior to enrollment, a clinical diagnosis of primary Evans syndrome was made.\n* Platelet count \\\u003C 30×10\\^9\u002FL or Hb \\\u003C 100g\u002FL or symptomatic anemia within 48 hours before the first administration of study drug;\n* Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy or those who cannot chose other second-line therapy;\n* If receiving emergency care for ES, treatment should be stopped \\>2 weeks before first dose.\n* DAT positive (IgG+, with or without C3+).\n* The patient need to be in the state of active hemolysis.\n* With normal hepatic and renal functions.\n* ECOG performance status ≤2.\n* Cardiac function: New York Heart Association functional class ≤2.\n* For patients receiving maintenance treatment, corticosteroids must have a stable dose at least 2 weeks before the first administration, TPO receptor agonists and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of anti-CD20 antibody treatment was\\>6 months.The end of alkylating agent treatment was\\>2 months.\n* Understand the study procedures and voluntarily sign the informed consent form in person.\n\nExclusion Criteria:\n\n* Secondary Evans syndrome. Received any treatment of anti-CD38 antibody drug\n* Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases;\n* HIV positive;\n* Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive;\n* Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc.;\n* At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled;\n* Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis;\n* Those who have received allogeneic stem cell transplantation or organ transplantation in the past;\n* Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up;\n* Patients whose toxic symptoms caused by pre-trial treatment have not disappeared;\n* Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.);\n* Patients with septicemia or other irregular severe bleeding;\n* Patients taking antiplatelet drugs at the same time;\n* Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients.","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and\u002For TPO-RA, or those in whom no other second-line treatment options are suitable.",[27,28],"Evan Syndrome","Treatment","RECRUITING","2025-02-20",{"date":32,"type":33},"2025-02-21","ACTUAL",{"date":35,"type":33},"2023-12-01",{"date":37,"type":21},"2025-08",{"name":39,"class":40},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100438792","phase-2-avatrombopag-in-the-treatment-of-adult-immune-thrombocytopenia-with-autoantibodies-100438792","NCT04993885","Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies","Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial","Inclusion Criteria:\n\n* The patients have provided written informed consent prior to enrollment.\n* Men and women greater than or equal to 18 years of age.\n* Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome.\n* Platelet count\\\u003C30 ×10\\^9\u002FL at screening.\n* Patients who have previously failed to receive Eltrombopag or Herombopag \\[poor efficacy (Eltrombopag 75 mg\u002Fd or Herombopag 7.5 mg\u002FD, at least 4 weeks), or the efficacy cannot be maintained\\], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment.\n* Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment.\n* Effective contraceptive measures will be taken during the clinical trial.\n\nExclusion Criteria:\n\n* Patients with active thyroid disease requiring treatment.\n* Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening.\n* Those who had received rituximab within 3 months.\n* Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks).\n* Subjects known to be allergic to Avatrombopag or any of its excipients.\n* Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months.\n* Patients with lupus encephalopathy or lupus nephritis.\n* Patients with cataract.\n* Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening.\n* Existing hepatitis B virus, hepatitis C virus replication or HIV infection.\n* Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase \\> 3×ULN).\n* Patients with severe cardiac or pulmonary dysfunction.\n* Severe renal damage (creatinine clearance \\\u003C 30 ml\u002Fmin).\n* There are surgical planners during the study.\n* History of psychiatric disorder.\n* Pregnant or lactating women or those planning to be pregnant during the trial.\n* Patients with a history of drug\u002Falcohol abuse (within 2 years before the study).\n* Patients that had participated in other experimental researches within one month before enrollment.\n* Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.",{"count":50,"type":21},52,[24],"This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.",[54,55,27,56],"Immune Thrombocytopenia","Autoantibodies","Connective Tissue Diseases",{"date":58,"type":33},"2025-02-24",{"date":60,"type":33},"2021-09-01",{"date":62,"type":21},"2025-09-30",{"name":39,"class":40}]